Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.40 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3590769 | 0.85 | MAOB (0.46) | MAOBMAOAPARP10PKMMET | |
| Lithium Ion SCHEMBL3590770 | 0.84 | MAOB (0.42) | MAOBMAOAPARP14PARP10PKM | |
| SCHEMBL3275073 | 0.79 | PARP10 (0.51) | MAOBPARP14PARP10ALOX5AP | |
| SCHEMBL3275520 | 0.77 | MAOB (0.46) | MAOBMAOAPARP14PARP10ALOX5AP | |
| SCHEMBL25934294 | 0.76 | CRBN (0.47) | MAOBMAOAPARP14PARP10 | |
| SCHEMBL24302655 | 0.76 | ALDH1A1 (0.40) | MAOBPARP10PKMALOX5APALOX5 | |
| SCHEMBL14893940 | 0.76 | MAOB (0.63) | MAOBMAOAPARP14PARP10 | |
| SCHEMBL176858 | 0.76 | MAOB (0.59) | MAOBMAOAPARP14PARP10NOX1 | |
| SCHEMBL12355689 | 0.73 | RARA (0.53) | MAOBMAOA | |
| SCHEMBL4838140 | 0.73 | MAPT (0.46) | MAOBMAOAPARP14PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846950-B2 | Histamine H3 receptor inhibitors, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-7846950-B2 | Histamine H3 receptor inhibitors, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-7846950-B2 | Histamine H3 receptor inhibitors, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| EP-1805169-B1 | HISTAMINE H3 RECEPTOR INHIBITORS, THEIR PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20080015235-A1 | Histamine H3 Receptor Inhibitors, Preparation and Therapeutic Uses | JESUDASON CYNTHIA D | 2008-01-17 | — | — | US | disclosed |
| US-20080015235-A1 | Histamine H3 Receptor Inhibitors, Preparation and Therapeutic Uses | JESUDASON CYNTHIA D | 2008-01-17 | — | — | US | disclosed |
| US-20080015235-A1 | Histamine H3 Receptor Inhibitors, Preparation and Therapeutic Uses | JESUDASON CYNTHIA D | 2008-01-17 | — | — | US | disclosed |
| EP-1805169-A1 | HISTAMINE H3 RECEPTOR INHIBITORS, THEIR PREPARATION AND THERAPEUTIC USES | Eli Lilly and Company (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006044228-A1 | HISTAMINE H3 RECEPTOR INHIBITORS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015235-A1 | Histamine H3 Receptor Inhibitors, Preparation and Therapeutic Uses | HRH3, HRH4, HCRTR1 | MAOB 618/4885MAOA 832/4885PARP14 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.